Assertio医疗 ASRT 深 沪
已收盘 02-06 16:00:00 美东时间
12.74
+1.120
+9.64%
华盛通- 最 高12.95
- 今 开11.69
- 成交量 6.17万股
- 最 低 11.61
- 昨 收 11.62
- 总市值 8175.01万
- 52周最高 15.15
- 市盈率 静 --
- 换手率 0.96%
- 52周最低 7.7055
- 委 比 -70.94%
- 总股本 641.68万
- 历史最高 393.90
- 量 比 1.25
- 振 幅 11.53%
- 历史最低 7.7055
- 每 手 1
- 风险率 1.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
HC Wainwright & Co. Maintains Buy on Assertio Holdings, Raises Price Target to $35
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Holdings (NASDAQ:ASRT) with a Buy and raises the price target from $3 to $35.
01-05 20:23
Assertio Therapeutics Announces Leadership Change with CEO Resignation
The latest update is out from Assertio Therapeutics ( ($ASRT) ). On November 17...
2025-11-22 06:32
Assertio Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.
Assertio Holdings shares are trading higher after the company reported better-t...
2025-11-11 05:20
Assertio Holdings Q3 Adj. EPS $0.18 Beats $(0.09) Estimate, Sales $49.459M Beat $27.020M Estimate
Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $(0.09) by 311.76 percent. This is a 800 percent increase over earnings of $0.02 per share from
2025-11-11 05:14
Assertio Appoints Mark L. Reisenauer As CEO, Effective Immediately, Succeeding Brendan P. O'Grady
Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"),
2025-10-28 21:16
Assertio Announces Leadership Transition
Assertio Holdings appointed Mark L. Reisenauer as CEO, effective immediately, succeeding Brendan P. O’Grady. Reisenauer, with over 30 years of experience in oncology and specialty products, is expected to lead the company's growth and efficiency. Assertio will report third-quarter 2025 results on November 10, 2025, and provide guidance updates. The company emphasized Reisenauer's expertise and stakeholder benefits from his leadership. A live webc...
2025-10-28 13:15
Assertio Therapeutics Amends ROLVEDON Supply Agreement
Assertio Therapeutics ( ($ASRT) ) just unveiled an update. On October 7, 2025, ...
2025-10-11 05:18
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV
Assertio announced new real-world data on SYMPAZAN (clobazam) Oral Film in treating Lennox-Gastaut Syndrome (LGS), a severe childhood epilepsy. Presented at the 150th American Neurological Association meeting, the study highlights SYMPAZAN's use in clinical practice, particularly for patients with swallowing difficulties. SYMPAZAN is the only FDA-approved oral film formulation for LGS seizures in patients aged two and older. The study analyzed 18...
2025-09-15 13:00
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association
Assertio Holdings, Inc. announced it will present new data on SYMPAZAN (clobazam) Oral Film at the 150th American Neurological Association Annual Meeting. The presentation will include real-world evidence on patients with Lennox-Gastaut Syndrome. SYMPAZAN is the only FDA-approved oral film formulation for adjunctive seizure treatment in LGS. Important safety information and usage guidelines are provided, including risks of concomitant opioid use,...
2025-09-10 11:30
